Classification Nuance. The OpenFDA dataset, which draws from the Structured Product Labeling (SPL) files, often includes multiple classification fields, and the specific string "Phosphate Binder [EPC]" may only be assigned to a single product. The other drugs are likely classified using: More Specific Classes: Many of those drugs (like sevelamer, ferric citrate, etc.) may be classified by their specific mechanism or chemical group, which also acts as a phosphate binder. Example: A drug might be classified as "Iron-Containing Compound [EPC]" or "Aluminum-Containing Compound [EPC]" instead of the more general "Phosphate Binder [EPC]". Different Classification Fields: The NDC data contains several classification fields. You might be checking the Established Pharmacological Class (pharm_class_epc), but the other drugs might be listed under: Mechanism of Action (pharm_class_moa), Physiological Effect (pharm_class_pe)
  Home  

Enter a class name or drug name above to search the database.

Programmed Death Receptor-1 Blocking Antibody [EPC]

NDC Number Brand Name Generic Name Manufacturer Dosage Form DEA Sch. Marketing Start Date
0003-3734 OPDIVO nivolumab E.R. Squibb & Sons, L.L.C. INJECTION 2017-12-08
0003-3756 OPDIVO nivolumab E.R. Squibb & Sons, L.L.C. INJECTION 2021-08-30
0003-3772 OPDIVO nivolumab E.R. Squibb & Sons, L.L.C. INJECTION 2014-12-22
0003-3774 OPDIVO nivolumab E.R. Squibb & Sons, L.L.C. INJECTION 2014-12-22
0003-6120 OPDIVO QVANTIG nivolumab and hyaluronidase-nvhy E.R. Squibb & Sons, L.L.C. INJECTION, SOLUTION 2025-01-02
0003-7125 OPDUALAG nivolumab and relatlimab-rmbw E.R. Squibb & Sons, L.L.C. INJECTION 2022-03-18
0006-3026 KEYTRUDA pembrolizumab Merck Sharp & Dohme LLC INJECTION, SOLUTION 2015-01-15
0006-3083 KEYTRUDA QLEX pembrolizumab and berahyaluronidase alfa-pmph Merck Sharp & Dohme LLC INJECTION, SOLUTION 2025-09-19
0006-5083 KEYTRUDA QLEX pembrolizumab and berahyaluronidase alfa-pmph Merck Sharp & Dohme LLC INJECTION, SOLUTION 2025-09-19
0173-0898 Jemperli dostarlimab GlaxoSmithKline LLC INJECTION 2021-04-22
50242-917 TECENTRIQ atezolizumab Genentech, Inc. INJECTION, SOLUTION 2016-05-18
50242-918 TECENTRIQ atezolizumab Genentech, Inc. INJECTION, SOLUTION 2019-03-08
50242-933 Tecentriq Hybreza atezolizumab and hyaluronidase-tqjs Genentech, Inc. INJECTION 2024-09-12
50881-006 ZYNYZ retifanlimab-dlwr Incyte Corporation INJECTION 2023-03-22
70114-340 LOQTORZI toripalimab-tpzi Coherus BioSciences, Inc. INJECTION 2023-10-27
72579-121 TEVIMBRA tislelizumab-jsgr BeOne Medicines USA, Inc. INJECTION, SOLUTION, CONCENTRATE 2024-03-14



 [EPC] Established Pharmacological Classification 

Loading full table content...